Factors affecting the pharmacokinetics and pharmacodynamics of liposomal drugs

Journal of Liposome Research

Volumn 22, Issue 3, 2012, Pages 177-192

  Song, Gina ^a   Wu, Huali ^a   Yoshino, Keisuke ^d   Zamboni, William C ^a,b,c  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b University of North Carolina at Chapel Hill   (United States)

^c North Carolina Biomedial Innovation Network   (United States)

^d TERUMO CORPORATION   (Japan)

Author keywords

Liposomes; Pharmacodynamics; Pharmacokinetics

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; ANNAMYCIN; ANTISENSE OLIGODEOXYNUCLEOTIDE; BELOTECAN; BUSULFAN; CISPLATIN; CPX 351; CYTARABINE; DAUNORUBICIN; DOXORUBICIN; EMEPEPIMUT S; FLUOROURACIL; GLYCOCHOLIC ACID; IHL 305; IRINOTECAN; LERAFAON; LIPOPLATIN; LIPOSOME; LIPOXAL; LURTOTECAN; MIFAMURTIDE; MITOPODOZIDE; OXALIPLATIN; PACLITAXEL; TOPOTECAN; UNCLASSIFIED DRUG; VINCRISTINE SULFATE;

DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG TARGETING; HUMAN; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS; CHEMISTRY, PHARMACEUTICAL; CLINICAL TRIALS AS TOPIC; DOXORUBICIN; DRUG DELIVERY SYSTEMS; DRUG INTERACTIONS; HUMANS; LIPID BILAYERS; LIPOSOMES; NEOPLASMS; PARTICLE SIZE; SURFACE PROPERTIES; TIME FACTORS; TISSUE DISTRIBUTION;

EID: 84865232192     PISSN: 08982104     EISSN: 15322394     Source Type: Journal    
DOI: 10.3109/08982104.2012.655285     Document Type: Review

References (125)

1. Abra, R. M., Hunt, C. A. (1981). Liposome disposition in vivo. III. Doseand vesicle-size effects. Biochim Biophys Acta 666:493-503 (Pubitemid 12144883)
2. Alexis, F., Prindgen, E., Molnar, L. K., Farokhzad, O. C. (2008). Factors affecting the clearance and biodistribution of polymericnanoparticles. Mol Pharm 5:505-515
3. Allen, T. M. (1981). A study of phospholipid interaction betweenhigh-density lipoproteins and small unilamellar vesicles. BiochimBiophys Acta 640:385-397
4. Allen, T. M., Cheng, W. W., Hare, J. I., Laginha, K. M. (2006). Pharmacokinetics and pharmacodynamics of lipidic nanoparticlesin cancer. Anticancer Agents Med Chem 6:513-523 (Pubitemid 44697110)
5. Allen, T. M., Hansen, C. (1991). Pharmacokinetics of stealth versusconventional liposomes: effect of dose. Biochim Biophys Acta1068:133-141
6. Allen, T. M., Smuckler, E. A. (1985). Liver pathology accompanyingchronic liposome administration in mouse. Res Commun ChemPathol Pharmacol 50:281-290 (Pubitemid 16212440)
7. Amantea, M. A., Forrest, A., Northfelt, D. W., Mamelok, R. (1997). Population pharmacokinetics and pharmacodynamics ofpegylated liposomal doxorubicin in patients with AIDS-relatedKaposi's sarcoma. Clin Pharmacol Ther 61:301-311 (Pubitemid 27145431)
8. Banerjee, J., Hanson, A. J., Gadam, B., Elegbede, A. I., Tobwala, S., Ganguly, B., et al. (2009). Release of liposomal contents bycell-secreted matrix metalloproteinase-9. Bioconjug Chem20:1332-133
9. Batist, G., Barton, J., Chaikin, P., Swenson, C., Welles, L. (2002). Myocet(liposome-encapsulated doxorubicin citrate): a new approach inbreast cancer therapy. Expert Opin Pharmacother 3:1739-175
10. Berry, G., Billingham, M., Alderman, E., Richardson, P., Torti, F., Lum, B., et al. (1998). The use of cardiac biopsy to demonstrate reducedcardiotoxicity in AIDS Kaposi's sarcoma patients treated withpegylated liposomal doxorubicin. Ann Oncol 9:711-716 (Pubitemid 28394155)
11. Booser, D. J., Esteva, F. J., Rivera, E., Valero, V., Esparza-Guerra, L., Priebe, W., et al. (2002). Phase II study of liposomal annamycinin the treatment of doxorubicin-resistant breast cancer. CancerChemother Pharmacol 50:6-8. (Pubitemid 34743989)
12. Campbell, R. B., Fukumura, D., Brown, E. B., Mazzola, L. M., Izumi, Y., Jain, R. K., et al. (2002). Cationic charge determines thedistribution of liposomes between the vascular and extravascularcompartments of tumors. Cancer Res 62:6831-683
13. Campbell, R. B., Ying, B., Kuesters, G. M., Hemphill, R. (2009). Fightingcancer: from the bench to bedside using second generationcationic liposomal therapeutics. J Pharm Sci 98:411-429
14. Chang, D. K., Lin, C. T., Wu, C. H., Wu, H. C. (2009). A novel peptideenhances therapeutic efficacy of liposomal anti-cancer drugs inmice models of human lung cancer. PLoS One 4:e4171.
15. Charrois, G. J., Allen, T. M. (2003). Multiple injections of pegylatedliposomal doxorubicin: pharmacokinetics and therapeutic activity. J Pharmacol Exp Ther 306:1058-106
16. Charrois, G. J., Allen, T. M. (2003). Rate of biodistribution of STEALTHliposomes to tumor and skin: influence of liposome diameter andimplications for toxicity and therapeutic activity. Biochim BiophysActa 1609:102-108. (Pubitemid 36044071)
17. Chonn, A., Semple, S. C., Cullis, P. R. (1992). Association of bloodproteins with large unilamellar liposomes in vivo. Relation tocirculation lifetimes. J Biol Chem 267:18759-18765.
18. Clemons, K. V., Stevens, D. A. (1998). Comparison of fungizone, amphotec, ambisome, and abelcet for treatment of systemicmurine cryptococcosis. Antimicrob Agent Chemother 42:899-902 (Pubitemid 28216375)
19. Conwell, C. C., Huang, L. (2005). Recent advances in non-viral genedelivery. Adv Genet 53PA:1-18.
20. Cullis, P. R., Chonn, A., Semple, S. C. (1998). Interactions of liposomesand lipid-based carrier systems with blood proteins: relation toclearance behaviour in vivo. Adv Drug Deliv Rev 32:3-17. (Pubitemid 28277172)
21. Dark, G. G., Calvert, A. H., Grimshaw, R., Poole, C., Swenerton, K., Kaye, S., et al. (2005). Randomized trial of two intravenous schedules ofthe topoisomerase I inhibitor liposomal lurtotecan in women withrelapsed epithelial ovarian cancer: a trial of the national cancerinstitute of Canada clinical trials group. J Clin Oncol 23:1859-1866. (Pubitemid 46211363)
22. Davis, S. C., Szoka, F. C., Jr. (1998). Cholesterol phosphate derivativessynthesisand incorporation into a phosphatase and calciumsensitivetriggered release liposome. Bioconjug Chem 9:783-792 (Pubitemid 28542247)
23. Dokka, S., Toledo, D., Shi, X., Castranova, V., Rojanasakul, Y. (2000). Oxygen radical-mediated pulmonary toxicity induced by somecationic liposomes. Pharm Res 17:521-525 (Pubitemid 30416388)
24. Dos Santos, N., Mayer, L. D., Abraham, S. A., Gallagher, R. C., Cox, K. A., Tardi, P. G., et al. (2002). Improved retention of idarubicin afterintravenous injection obtained for cholesterol-free liposomes. Biochim Biophys Acta 1561:188-201 (Pubitemid 34454786)
25. Dromi, S., Frenkel, V., Luk, A., Traughber, B., Angstadt, M., Bur, M., et al. (2007). Pulsed-high intensity focused ultrasound and lowtemperature- sensitive liposomes for enhanced targeted drugdelivery and antitumor effect. Clin Cancer Res 13:2722-272
26. Drummond, D. C., Meyer, O., Hong, K., Kirpotin, D. B., Papahadjopoulos, D. (1999). Optimizing liposomes for delivery of chemotherapeuticagents to solid tumors. Pharmacol Rev 51:691-743
27. Drummond, D. C., Noble, C. O., Guo, Z., Hayes, M. E., Connolly-Ingram, C., Gabriel, B. S., et al. (2010). Development of a highlystable and targetable nanoliposomal formulation of topotecan. J Control Release 141:13-21.
28. Drummond, D. C., Noble, C. O., Hayes, M. E., Park, J. W., Kirpotin, D. B. (2008). Pharmacokinetics and in vivo drug releaserates in liposomal nanocarrier development. J Pharm Sci 97:4696-474
29. Duffaud, F., Borner, M., Chollet, P., Vermorken, J. B., Bloch, J., Degardin, M., et al. (2004). Phase II study of OSI-211 (liposomallurtotecan) in patients with metastatic or loco-regional recurrent squamous cell carcinoma of the head and neck. An EORTC NewDrug Development Group study. Eur J Cancer 40:2748-275
30. Eavarone, D. A., Yu, X., Bellamkonda, R. V. (2000). Targeted drugdelivery to C6 glioma by transferrin-coupled liposomes. J BiomedMater Res 51:10-14. (Pubitemid 30331976)
31. Ellens, H., Morselt, H. W., Dontje, B. H., Kalicharan, D., Hulstaert, C. E., Scherphof, G. L. (1983). Effects of liposome dose and thepresence of lymphosarcoma cells on blood clearance and tissuedistribution of large unilamellar liposomes in mice. Cancer Res43:2927-293
32. Epstein-Barash, H., Gutman, D., Markovsky, E., Mishan-Eisenberg, G., Koroukhov, N., Szebeni, J., et al. (2010). Physicochemicalparameters affecting liposomal bisphosphonates bioactivity forrestenosis therapy: internalization, cell inhibition, activationof cytokines and complement, and mechanism of cell death. J Control Release 146:182-195
33. Ewer, M. S., Martin, F. J., Henderson, C., Shapiro, C. L., Benjamin, R. S., Gabizon, A. A. (2004). Cardiac safety of liposomal anthracyclines. Semin Oncol 31:161-181 (Pubitemid 40023246)
34. Fassas, A., Anagnostopoulos, A. (2005). The use of liposomaldaunorubicin (DaunoXome) in acute myeloid leukemia. LeukLymphoma 46:795-802 (Pubitemid 40959668)
35. Federman, N., Denny, C. T. (2010). Targeting liposomes toward novelpediatric anticancer therapeutics. Pediatr Res 67:514-519
36. Fedier, A., Poyet, C., Perucchini, D., Boulikas, T., Fink, D. (2006). MLH1-deficient tumor cells are resistant to lipoplatin, but retainsensitivity to lipoxal. Anticancer Drugs 17:315-323
37. Felman, E. J., Lancet, J. E., Kolitz, J. E., Ritchie, E. K., Roboz, G. J., List, A. F., et al. (2011). First-in-man study of CPX-351: a liposomalcarrier containing cytarabine and daunorubicin in a fixed 5:1molar ratio for the treatment of relapsed and refractory acutemyeloid leukemia. J Clin Oncol 29:979-985
38. Fujita, T. (1974). A scanning electron microscope study of the humanspleen. Arch Histol Jpn 37:187-216
39. Gabizon, A. A., Barenholz, Y., Bialer, M. (1993). Prolongation of the circulation time of doxorubicin encapsulated in liposomescontaining a polyethylene glycol-derivatized phospholipid:pharmacokinetic studies in rodents and dogs. Pharm Res10:703-708. (Pubitemid 23152316)
40. Gabizon, A., Catane, R., Uziely, B., Kaufman, B., Safra, T., Cohen, R., et al. (1994). Prolonged circulation time and enhancedaccumulation in malignant exudates of doxorubicin encapsulatedin polyethylene-glycol coated liposomes. Cancer Res54:987-992. (Pubitemid 24085451)
41. Gabizon, A., Goren, D., Cohen, R., Barenholz, Y. (1998). Developmentof liposomal anthracyclines: from basics to clinical applications. J Control Release 53:275-279 (Pubitemid 28218710)
42. Gabizon, A., Isacson, R., Rosengarten, O., Tzemach, D., Shmeeda, H., Sapir, R. (2008). An open-label study to evaluate dose and cycledependence of the pharmacokinetics of pegylated liposomaldoxorubicin. Cancer Chemother Pharmacol 61:695-702
43. Gabizon, A., Shmeeda, H., Barenholz, Y. (2003). Pharmacokinetics ofpegylated liposomal doxorubicin: review of animal and humanstudies. Clin Pharmacokinet 42:419-436 (Pubitemid 36649037)
44. Gabizon, A., Tzemach, D., Gorin, J., Mak, L., Amitay, Y., Shmeeda, H., et al. (2010). Improved therapeutic activity of folate-targetedliposomal doxorubicin in folate receptor-expressing tumor models. Cancer Chemother Pharmacol 66:43-52.
45. Gabizon, A., Tzemach, D., Mak, L., Bronstein, M., Horowitz, A. T. (2002). Dose dependency of pharmacokinetics and therapeuticefficacy of pegylated liposomal doxorubicin (DOXIL) in murinemodels. J Drug Target 10:539-548 (Pubitemid 36124352)
46. Giles, F. J., Tallman, M. S., Garcia-Manero, G., Cortes, J. E., Thomas, D. A., Wierda, W. G., et al. (2004). Phase I and pharmacokineticstudy of a low-clearance, unilamellar liposomal formulation oflurtotecan, a topoisomerase 1 inhibitor, in patients with advancedleukemia. Cancer 100:1449-145
47. Gregoriadis, G., Senior, J. (1982). Control of fate and behaviour ofliposomes in vivo. Prog Clin Biol Res 102:263-279
48. Hassan, M., Nilsson, C., Hassan, Z., Gungor, T., Aschan, J., Winiarski, J., et al. (2002). A phase II trial of liposomal busulphan as anintravenous myeloablative agent prior to stem cell transplantation:500 mg/m(2) as a optimal total dose for conditioning. Bone MarrowTransplant 30:833-841 (Pubitemid 36097471)
49. Hempel, G., Reinhardt, D., Creutzig, U., Boos, J. (2003). Populationpharmacokinetics of liposomal daunorubicin in children. Br J ClinPharmacol 56:370-377
50. Hong, Y., Shaw, P. J., Nath, C. E., Yadav, S. P., Stephen, K. R., Earl, J. W., Mclachlan, A. J. (2006). Population pharmacokinetics of liposomalamphotericin B in pediatric patients with malignant diseases. Antimicrob Agents Chemother 50:935-942 (Pubitemid 43327797)
51. Hubert, A., Lyass, O., Pode, D., Gabizon, A. (2000). Doxil (Caelyx): anexploratory study with pharmacokinetics in patients with hormonerefractoryprostate cancer. Anticancer Drugs 11:123-127 (Pubitemid 30193068)
52. Igarashi, E. (2008). Factors affecting toxicity and efficacy of polymericnanomedicines. Toxicol Appl Pharmacol 229:121-34.
53. Janoff, A. S., Boni, L. T., Popescu, M. C., Minchey, S. R., Cullis, P. R., Madden, T. D., et al. (1988). Unusual lipid structures selectivelyreduce the toxicity of amphotericin B. Proc Natl Acad Sci U S A85:6122-6126.
54. Jones, S. F., Zamboni, W. C., Burris, H. A., III, Chan, E., Infante, J. R., Keedy, V., et al. (2009). Phase I and pharmacokinetic (PK) studyof IHL-305 (pegylated liposomal irinotecan) in patients withadvanced solid tumors. Presented at the 45th Annual Meeting ofthe American Society of Clinical Oncology at Orlando, Florida, USA, June 1, 2009.
55. Kobayashi, T., Ishida, T., Okada, Y., Ise, S., Harashima, H., Kiwada, H. (2007). Effect of transferrin receptor-targeted liposomaldoxorubicin in P-glycoprotein-mediated drug resistant tumorcells. Int J Pharm 329:94-102. (Pubitemid 44937528)
56. Krown, S. E., Northfelt, D. W., Osoba, D., Stewart, J. S. (2004). Useof liposomal anthracyclines in Kaposi's sarcoma. Semin Oncol31:36-52. (Pubitemid 40023241)
57. La-Beck, N. M., Wu, H., Infante, J. R., Jones, S. F., Burris, H. A., III, Keedy, V. L., et al. (2010). The evaluation of gender on thepharmacokinetics (PK) of pegylated liposomal anticancer agents. Presented at the 2010 American Society of Clinical OncologyAnnual Meeting. J Clin Oncol 28(Suppl. ):e13003.
58. La-Beck, N. M., Zamboni, B. A., Gabizon, A., Schmeeda, H., Amanta, M., Gehrig, P. A., et al. (2012). Factors affecting thepharmacokinetics of pegylated liposomal doxorubicin in patients. Cancer Chemother Pharmacol 69:43-50.
59. Laginha, K., Mumbengegwi, D., Allen, T. (2005). Liposomes targetedvia two different antibodies: assay, B-cell binding, and cytotoxicity. Biochim Biophys Acta 1711:25-32. (Pubitemid 40726397)
60. Laniado-Laborin, R., Cabrales-Vargas, M. N. (2009). Amphotericin B:side effects and toxicity. Rev Iberoam Micol 26:223-227.
61. Lenaerts. V., Couvreur, P., Christiaens-Lehy, D., Joiris, E., Roland, M., Rollman, B., et al. (1984). Degradation of poly (isobutylcyanocrylate) nanoparticles. Biomaterials 5:65-68.
62. Li, S. D., Huang, L. (2008). Pharmacokinetics and biodistribution ofnanoparticles. Mol Pharm 5:496-504.
63. Lindner, L. H., Eichhorn, M. E., Eibl, H., Teichert, N., Schmitt-Sody, M., Issels, R. D., Dellian, M. (2004). Novel temperature-sensitiveliposomes with prolonged circulation time. Clin Cancer Res10:2168-2178. (Pubitemid 38375579)
64. Lindner, L. H., Hossann, M. (2010). Factors affecting drug release fromliposomes. Curr Opin Drug Discov Devel 13:111-123.
65. Liu, D., Mori, A., Huang, L. (1992). Role of liposome size and RESblockade in controlling biodistribution and tumor uptake of GM1-containing liposomes. Biochim Biophys Acta 1104:95-101.
66. Lyass, O., Hubert, A., Gabizon, A. A. (2001). Phase I study of doxilcisplatincombination chemotherapy in patients with advancedmalignancies. Clin Cancer Res 7:3040-3046. (Pubitemid 32963822)
67. Lyass, O., Uziely, B., Beb-Yosef, R., Tzemach, D., Hsdhing, N. I., Lotem, M., et al. (2000). Correlation of toxicity with pharmacokinetics ofpegylated liposomal doxorubicin (Doxil) in metastatic breastcarcinoma. Cancer 89:1037-1047.
68. Maeda, H., Bharate, G. Y., Daruwalla, J. (2009). Polymeric drugs forefficient tumor-targeted drug delivery based on EPR-effect. Eur JPharm Biopharm 71:409-419.
69. Markman, M., Gordon, A. N., Mcquire, W. P., Muggia, F. M. (2004). Liposomal anthracycline treatment for ovarian cancer. SeminOncol 31:91-105. (Pubitemid 40023243)
70. Meers, P. (2001). Enzyme-activated targeting of liposomes. Adv DrugDeliv Rev 53:265-272. (Pubitemid 34026337)
71. Metselaar, J. M., Bruin, P., De Boer, L. W., De Vringer, T., Snel, C., Oussoren, C., et al. (2003). A novel family of L-amino acid-basedbiodegradable polymer-lipid conjugates for the development oflong-circulating liposomes with effective drug-targeting capacity. Bioconjug Chem 14:1156-1164. (Pubitemid 37449043)
72. Nardin, A., Lefebvre, M. L., Labroquere, K., Faure, O., Abastado, J. P. (2006). Liposomal muramyl tripeptide phosphatidylethanolamine:targeting and activating macrophages for adjuvant treatment ofosteosarcoma. Curr Cancer Drug Targets 6:123-133.
73. Needham, D., Anyarambhatla, G., Kong, G., Dewhirst, M. W. (2000). A new temperature-sensitive liposome for use with mildhyperthermia: characterization and testing in a human tumorxenograft model. Cancer Res 60:1197-1201. (Pubitemid 30151982)
74. Newman, M. S., Colbern, G. T., Working, P. K., Engbers, C., Amantea, M. A. (1999). Comparative pharmacokinetics, tissue distribution, and therapeutic effectiveness of cisplatin encapsulated in longcirculating, pegylated liposomes (SPI-077) in tumor-bearing mice. Cancer Chemother Pharmacol 43:1-7. (Pubitemid 29048341)
75. Nicoletto, M. O., Bertorelle, R., Borgato, L., De Salvo, G. L., Artioli, G., Lombardi, G., et al. (2009). Family history of cancer rather thanp53 status predicts efficacy of pegylated liposomal doxorubicinand oxaliplatin in relapsed ovarian cancer. Int J Gynecol Cancer19:1022-1028.
76. Niu, M. M., Lu, Y., Hovgaard, L., Wu, W. (2011). Liposomescontaining glycocholate as potential oral insulin deliverysystems: preparation, in vitro characterization, and improvedprotection against enzymatic degradation. Int J Nanomedicine 6:1155-1166.
77. Noble, C. O., Kirpotin, D. B., Hayes, M. E., Mamot, C., Hong, K., Park, J. W., et al. (2004). Development of ligand-targeted liposomes forcancer therapy. Expert Opin Ther Targets 8:335-353. (Pubitemid 39117698)
78. Noguchi, Y., Wu, J., Duncan, R., Strohalm, J., Ulbrich, K., Akaike, T., et al. (1998). Early phase tumor accumulation of macromolecules: A great difference in clearance rate between tumor and normaltissues. Jpn J Cancer Res 89:307-314. (Pubitemid 28197296)
79. Northfelt, D. W., Martin, F. J., Working, P. (1996). Doxorubicin encapsulatedin liposomes containing surface-bound polyethyleneglycol: pharmacokinetics, tumor localization, and safety in patients withAIDS-related Kaposi's sarcoma. J Clin Pharmcol 36:55-63. (Pubitemid 26058811)
80. Oja, C. D., Semple, S. C., Chonn, A., Cullis, P. R. (1996). Influenceof dose on liposome clearance: critical role of blood proteins. Biochim Biophys Acta 1281:31-37. (Pubitemid 26178845)
81. Paliwal, S. R., Paliwal, R., Mishra, N., Mehta, A., Vyas, S. P. (2010). Anovel cancer targeting approach based on estrone anchored stealthliposome for site-specific breast cancer therapy. Curr Cancer DrugTargets 10:343-353.
82. Papahadjopoulos, D., Allen, T. M., Gabizon, A., Mayhew, E., Matthay, K., Huang, S. K., et al. (1991). Sterically stabilized liposomes:improvements in pharmacokinetics and antitumor therapeuticefficacy. Proc Natl Acad Sci U S A 88:11460-11464. (Pubitemid 21916061)
83. Park, J. W., Kirpotin, D. B., Hong, K., Shalaby, R., Shao, Y., Nielsen, U. B., et al. (2001). Tumor targeting using anti-her2 immunoliposomes. JControl Release 74:95-113. (Pubitemid 32727613)
84. Phuphanich, S., Maria, B., Braeckman, R., Chamberlain, M. (2007). Apharmacokinetic study of intra-CSF administered encapsulatedcytarabine (DepoCyt) for the treatment of neoplastic meningitisin patients with leukemia, lymphoma, or solid tumors as part of aphase III study. J Neurooncol 81:201-208. (Pubitemid 44963980)
85. Pisarik, L., Joly, V., Jullien, S., Carbon, C., Yeni, P. (1990). Reductionof free amphotericin B acute toxicity in mice after intravenousadministration of empty liposomes. J Infect Dis 161:1042-1044. (Pubitemid 20148357)
86. Ravaioli, A., Papi, M., Pasquini, E., Marangolo, M., Runas, B., Fantini, M., et al. (2009). Lipoplatin monotherapy: a phase II trial ofsecond-line treatment of metastatic non-small-cell lung cancer. J Chemother 21:86-90.
87. Rose, P. G. (2005). Pegylated liposomal doxorubicin: optimizing thedosing schedule in ovarian cancer. Oncologist 10:205-214. (Pubitemid 40463158)
88. Rudin, C. M., Marshall, J. L., Huang, C. H., Kindler, H. L., Zhang, C., Kumar, D., et al. (2004). Delivery of a liposomal c-raf-1 antisenseoligonucleotide by weekly bolus dosing in patients with advancedsolid tumors: a phase I study. Clin Cancer Res 10:7244-7251. (Pubitemid 39487711)
89. Samad, A., Sultana, Y., Aqil, M. (2007). Liposomal drug deliverysystems: an update review. Curr Drug Deliv 4:297-305. (Pubitemid 47554274)
90. Sangha, R., Butts, C. (2007). L-BLP25: a peptide vaccine strategy innon small cell lung cancer. Clin Cancer Res 13:s4652-s4654.
91. Sapra, P., Allen, T. M. (2003). Ligand-targeted liposomal anticancerdrugs. Prog Lipid Res 42:439-462.
92. Scheule, R. K., St., George, J. A., Bagley, R. G., Marshall, J., Kaplan, J. M., Akita, G. Y., et al. (1997). Basis of pulmonary toxicity associatedwith cationic lipid-mediated gene transfer to the mammalian lung. Hum Gene Ther 8:689-707. (Pubitemid 27202056)
93. Schmitt-Sody, M., Strieth, S., Krasnici, S., Sauer, B., Schulze, B., Teifel, M., et al. (2003). Neovascular targeting therapy: paclitaxelencapsulated in cationic liposomes improves antitumoral efficacy. Clin Cancer Res 9:2335-2341. (Pubitemid 36687660)
94. Schroeder, A., Kost, J., Barenholz, Y. (2009). Ultrasound, liposomes, and drug delivery: principles for using ultrasound to controlthe release of drugs from liposomes. Chem Phys Lipids162:1-16.
95. Seetharamu, N., Kim, E., Hochster, H., Martin, F., Muggia, F. (2010). Phase II study of liposomal cisplatin (SPI-77) in platinum-sensitiverecurrences of ovarian cancer. Anticancer Res 30:541-545.
96. Sidone B. J., Edwards, R. P., Zamboni, B. A. (2007). Evaluation ofbody surface area (BSA) based dosing, age, and body compositionas factors affecting the pharmacokinetics (PK) variability ofPEGYLATED liposomal doxorubicin (Doxil). Presented at the 2007AACR-NCI-EORTC conference, San Francisco, California, USA, October 22-26, 2007.
97. Siegal, T., Horowitz, A., Gabizon, A. (1995). Doxorubicin encapsulatedin sterically stabilized liposomes for the treatment of a brain tumormodel: biodistribution and therapeutic efficacy. J Neurosurg83:1029-1037. (Pubitemid 26048143)
98. Shmeeda, H., Tzemach, D., Mak, L., Gabizon, A. (2009). Her2-targetedpegylated liposomal doxorubicin: retention of target-specific bindingand cytotoxicity after in vivo passage. J Control Release 136:155-160.
99. Soni, V., Kohli, D. V., Jain, S. K. (2008). Transferrin- conjugatedliposomal system for improved delivery of 5-fluorouracil to brain. J Drug Target 16:73-78.
100. Song, G., Wu, H., La-Beck, N., Zamboni, B. A., Strychor, S., Zamboni, W. C. (2009). Effect of gender on pharmacokinetic dispositionof pegylated liposomal CKD-602 (S-CKD602) and optisomaltopotecan (TLI) in rats [poster presentation]. Presented at the2009 American Association of Cancer Research Annual Meeting atWashington, DC. Abstract #3700.
101. Spira, J., Plyushch, O. P., Andreeva, T. A., Andreev, Y. (2006). Prolonged bleeding-free period following prophylactic infusion ofrecombinant factor VIII reconstituted with pegylated liposomes. Blood 108:3668-3673. (Pubitemid 44864543)
102. Stathopoulos, G. P., Boulikas, T., Kourvetaris, A., Stathopoulos, J. (2006). Liposomal oxaliplatin in the treatment of advanced cancer: A phase I study. Anticancer Res 26:1489-1493.
103. Tailor, T. D., Hanna, G., Yarmolenko, P. S., Dreher, M. R., Betof, A. S., Nixon, A. B., et al. (2010). Effect of pazopanib on tumor microenvironmentand liposome delivery. Mol Cancer Ther 9:1798-1808.
104. Takeuchi, H., Kojima, H., Yamamoto, H., Kawashima, Y. (2001). Evaluation of circulation profiles of liposomes coated withhydrophilic polymers having different molecular weight in rats. J Control Release 75:83-91. (Pubitemid 32635199)
105. Torchillin, V. P., Levchenko, T. S., Whiteman, K. R., Yaroslavov, A. A., Tsatsakis, A. M., Rizos, A. K., et al. (2001). Amphiphilicpoly-N- vinylpyrrolidones:synthesis, properties, and liposomesurface modification. Biomaterials 22:3035-3044. (Pubitemid 32768711)
106. Torchilin, V. P. (2005). Recent advances with liposomes aspharmaceutical carriers. Nat Rev Drug Discov 4:145-160. (Pubitemid 40282557)
107. Veal, G. J., Griffin, M. J., Price, E., Parry, A., Dick, G. S., Little, M. A., et al. (2001). A phase I study in paediatric patients to evaluate thesafety and pharmacokinetics of SPI-077, a liposome encapsulatedformulation of cisplatin. Br J Cancer 84:1029-1035. (Pubitemid 32448497)
108. Veerareddy, P. R., Vobalaboina, V. (2004). Lipid-based formulations ofamphotericin B. Drugs Today (Barc) 40:133-145.
109. Wang, J., Sui, M., Fan, W. (2010). Nanoparticles for tumor targetedtherapies and their pharmacokinetics. Curr Drug Metab11:129-141.
110. Whiteman, K. R., Subr, V., Ulbrich, K., Torchillin, V. P. (2001). Poly(HPMA)-coated liposomes demonstrate prolonged circulationin mice. J Liposome Res 11:153-164. (Pubitemid 33096375)
111. Woodle, M. C., Lasic, D. D. (1992). Sterically stabilized liposomes. Biochim Biophys Acta 1113:171-199.
112. Working, P. K., Dayan, A. D. (1996). Pharmacological-toxicologicalexpert report. CAELYX. (Stealth liposomal doxorubicin HCl). HumExp Toxicol 15:751-785.
113. Wu, H., Ramanathan, R. K., Zamboni, B. A., Strychor, S., Ramalingam, S., Edwards, R. P., et al. (2011). Population pharmacokinetics ofpegylated liposomal CKD-602 (S-CKD602) in patients with advancedmalignancies. J Clin Pharmacol Jan 13. [Epub ahead of print]
114. Wu, H., Infante, J. R., Jones, S. F., III, Burris, H. A., Chan, E., Keedy, V. L., et al. (2009). Factors affecting the pharmacokinetics andpharmacodynamics of PEGylated liposomal irinotecan (IHL-305)in patients with advanced solid tumors. Abstract C127. In 2009AACR-NCI-EORTC International Conference on Molecular Targetsand Cancer Therapeutics.
115. Xiong, X. B., Huang, Y., Lu, W. L., Zhang, X., Zhang, H., Nagai, T., et al. (2005). Intracellular delivery of doxorubicin with RGD-modifiedsterically stabilized liposomes for an improved antitumor efficacy:in vitro and in vivo. J Pharm Sci 94:1782-1793. (Pubitemid 41360872)
116. Yoo, G. H., Hung, M. C., Lopez-Berestein, G., Lafollette, S., Ensley, J. F., Carey, M., et al. (2001). Phase I trial of intratumoral liposome E1Agene therapy in patients with recurrent breast and head and neckcancer. Clin Cancer Res 7:1237-1245. (Pubitemid 32708675)
117. Yuan, F., Dellian, M., Fukumura, D., Leunig, M., Berk, D. A., Torchilin, V. P., et al. (1995). Vascular permeability in a human tumorxenograft: molecular size dependence and cutoff size. Cancer Res55:3752-3726.
118. Yurkovetskiy, A. V., Hiller, A., Syed, S., Yin, M., Lu, X. M., Fischman, A. J., et al. (2004). Synthesis of a macromolecular camptothecinconjugate with dual phase drug release. Mol Pharm 1:375-382.
119. Zamboni, W. C. (2005). Liposomal, nanoparticle, and conjugatedformulations of anticancer agents. Clin Cancer Res 11:8230-8234. (Pubitemid 41746931)
120. Zamboni, W. C., Gervais, A. C., Egorin, M. J., Schellens, J. H., Zuhowski, E. G., Pluim, D., et al. (2004). Systemic and tumor disposition ofplatinum after administration of cisplatin or STEALTH liposomalcisplatinformulations (SPI-077 and SPI-077 B103) in a preclinicaltumor model of melanoma. Cancer Chemother Pharmacol53:329-336. (Pubitemid 38392358)
121. Zamboni, W. C., Maruca, L. J., Strychor, S., Zamboni, B. A., Ramalingam, S., Edwards, R. P., et al. (2011). Bidirectional pharmacodynamicinteraction between pegylated liposomal CKD-602 (S-CKD602)and monocytes in patients with refractory solid tumors. J LiposomeRes 21:158-165.
122. Zamboni, W. C., Eiseman, J. E., Strychor, S., Rice, P. M., Joseph, E., Potter, D. M., et al. (2006). Relationship between the plasmaand tumor disposition of STEALTH liposomal CKD-602 andmacrophages/dendritic cells (MDC) in mice bearing human tumorxenografts. Proc AACR 47:1280.
123. Zamboni, W. C., Edwards, R. P., Mountz, J. M. (2007). NSTI NanotechnologyConference. The development of liposomal and nanoparticleanticancer agents: Methods to evaluate the encapsulated andreleased drug in plasma and tumor and phenotypic probes for thepharmacokinetic and pharmacodynamic disposition.
124. Zamboni, W. C., Ramalingam, S., Friedland, D. M., Edwards, R. P., Stoller, R. G., Strychor, S., et al. (2009a). Phase I and pharmacokineticstudy of pegylated liposomal CKD-602 in patients with advancedmalignancies. Clin Cancer Res 15:1466-1472.
125. Zamboni, W. C., Strychor, S., Maruca, L., Ramaligam, S., Zamboni, B. A., Wu, H., et al. (2009b). Pharmacikinetic study of pegylatedliposomal CKD-602 (S-CKD602) in patients with advancedmalignancies. Clin Pharmacol Ther 86:519-526.